Kyverna reports Q1 net loss $39.7M; initiates rolling BLA for miv-cel in SPS

Kyverna Therapeutics, Inc.

2026-Q1 EPS reported -$0.66

Cash, cash equivalents and marketable securities of $236.4M as of March 31, 2026; cash runway expected into 2028.
Net loss of $39.7M ($0.66 per share) for Q1 2026; R&D expenses $30.1M, G&A $11.3M.
Initiated rolling BLA submission for miv-cel in stiff person syndrome after positive pre-BLA meeting with FDA; completion expected Q4 2026.
Primary analysis of KYSA-8 trial in SPS showed statistically significant durable benefit across all endpoints; 100% of patients free of immunotherapies at week 16.
Appointed Nadia Dac as Chief Commercial Officer; enrollment ongoing in Phase 3 gMG trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kyverna Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219377

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.